{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:00:49Z","timestamp":1790805649826,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.reth.2022.09.009","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T08:49:00Z","timestamp":1665737340000},"page":"442-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["CRISPR\/Cas9 and AAV mediated insertion of \u03b22 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8094-4284","authenticated-orcid":false,"given":"Sohsuke","family":"Meshitsuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9818-5880","authenticated-orcid":false,"given":"Ryo","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokiko","family":"Nagamura-Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyoshi","family":"Futami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9016-1948","authenticated-orcid":false,"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5411","key":"10.1016\/j.reth.2022.09.009_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.reth.2022.09.009_bib2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.reth.2022.09.009_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.reth.2022.09.009_bib4","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.stem.2012.03.007","article-title":"Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-\/FAS-mediated T cell apoptosis","volume":"10","author":"Akiyama","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"9419","key":"10.1016\/j.reth.2022.09.009_bib5","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Le Blanc","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.reth.2022.09.009_bib6","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s12015-022-10369-1","article-title":"A brief overview of global trends in MSC-based cell therapy","volume":"18","author":"Jovic","year":"2022","journal-title":"Stem Cell Rev Rep"},{"issue":"12","key":"10.1016\/j.reth.2022.09.009_bib7","doi-asserted-by":"crossref","first-page":"7761","DOI":"10.4049\/jimmunol.176.12.7761","article-title":"Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice","volume":"176","author":"Sudres","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.reth.2022.09.009_bib8","article-title":"Mesenchymal stromal\/stem cells in regenerative medicine and tissue engineering","volume":"2018","author":"Fitzsimmons","year":"2018","journal-title":"Stem Cell Int"},{"issue":"1","key":"10.1016\/j.reth.2022.09.009_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13287-016-0341-0","article-title":"Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015)","volume":"7","author":"Singh","year":"2016","journal-title":"Stem Cell Res Ther"},{"issue":"9624","key":"10.1016\/j.reth.2022.09.009_bib10","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.reth.2022.09.009_bib11","doi-asserted-by":"crossref","first-page":"F31","DOI":"10.1152\/ajprenal.00007.2005","article-title":"Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms","volume":"289","author":"T\u00f6gel","year":"2005","journal-title":"Am J Physiol Ren Physiol"},{"issue":"24","key":"10.1016\/j.reth.2022.09.009_bib12","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1021\/bi00748a001","article-title":"The complete amino acid sequence of beta 2-microglobulin","volume":"12","author":"Cunningham","year":"1973","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.reth.2022.09.009_bib13","article-title":"Efficient homology-directed gene editing by CRISPR\/Cas9 in human stem and primary cells using tube electroporation","volume":"8","author":"Xu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.reth.2022.09.009_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-065X.1999.tb01292.x","article-title":"Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers","volume":"168","author":"Cosman","year":"1999","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.reth.2022.09.009_bib15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00438-017-1404-3","article-title":"The impact of HLA-G, LILRB1 and LILRB2 gene polymorphisms on susceptibility to and severity of endometriosis","volume":"293","author":"Byli\u0144ska","year":"2018","journal-title":"Mol Genet Genom"},{"issue":"4952","key":"10.1016\/j.reth.2022.09.009_bib16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1126\/science.2326636","article-title":"A class I antigen, HLA-G, expressed in human trophoblasts","volume":"248","author":"Kovats","year":"1990","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.reth.2022.09.009_bib17","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.4049\/jimmunol.175.8.4866","article-title":"The CD85J\/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules","volume":"175","author":"Gonen-Gross","year":"2005","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.reth.2022.09.009_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.0001-2815.2004.00290.x","article-title":"The LILR family: modulators of innate and adaptive immune pathways in health and disease","volume":"64","author":"Brown","year":"2004","journal-title":"Tissue Antigens"},{"issue":"44","key":"10.1016\/j.reth.2022.09.009_bib19","doi-asserted-by":"crossref","first-page":"16412","DOI":"10.1073\/pnas.0605228103","article-title":"Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2\/LIR2\/ILT4\/CD85d)","volume":"103","author":"Shiroishi","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.reth.2022.09.009_bib20","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.4049\/jimmunol.167.4.1877","article-title":"Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells","volume":"167","author":"Rajagopalan","year":"2001","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.reth.2022.09.009_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.humimm.2012.11.022","article-title":"\u03b22-Microglobulin-free HLA-G activates natural killer cells by increasing cytotoxicity and proinflammatory cytokine production","volume":"74","author":"Zhao","year":"2013","journal-title":"Hum Immunol"},{"issue":"9","key":"10.1016\/j.reth.2022.09.009_bib22","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.leukres.2009.03.047","article-title":"A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naive T cells","volume":"33","author":"Narita","year":"2009","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.reth.2022.09.009_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231896","article-title":"The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells","volume":"15","author":"Futami","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.reth.2022.09.009_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nprot.2017.143","article-title":"CRISPR\/Cas9 genome editing in human hematopoietic stem cells","volume":"13","author":"Bak","year":"2018","journal-title":"Nat Protoc"},{"issue":"2","key":"10.1016\/j.reth.2022.09.009_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/scrt53","article-title":"Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia","volume":"2","author":"McGinley","year":"2011","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"10.1016\/j.reth.2022.09.009_bib26","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.reth.2022.09.009_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.reth.2022.09.009_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tmrv.2015.11.004","article-title":"Unraveling the mesenchymal stromal cells\u2019 paracrine immunomodulatory effects","volume":"30","author":"Fontaine","year":"2016","journal-title":"Transfus Med Rev"},{"issue":"6","key":"10.1016\/j.reth.2022.09.009_bib29","doi-asserted-by":"crossref","first-page":"R210","DOI":"10.1186\/ar3187","article-title":"Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis","volume":"12","author":"Liu","year":"2010","journal-title":"Arthritis Res Ther"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320422000955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320422000955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:39:36Z","timestamp":1762450776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352320422000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":29,"alternative-id":["S2352320422000955"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2022.09.009","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR\/Cas9 and AAV mediated insertion of \u03b22 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2022.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}